Anlon Healthcare Limited (AHCL)
Disclosure of material issue
Anlon Healthcare Limited incorporated a new subsidiary, Anlon Healthcare Nigeria Limited, on September 20, 2026.
- Subsidiary incorporated in Nigeria with authorized and paid-up capital of 100 million Naira
- Business focus: manufacturing and trading of APIs, bulk drugs, formulations, cosmetics, surgical implants, and medical devices
- Strategic intent: expand presence in West African market covering 16 countries
- Anlon Healthcare holds 90% equity in the subsidiary
- No governmental approvals required for incorporation
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 AHCL — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add AHCL to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Anlon Healthcare Limited
Important.
The summary above is generated automatically from Anlon Healthcare Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.